PhD Candidate
Servicio de Hematología, Hospital Universitario de Salamanca (HUS – IBSAL), CIBERONC y Centro de Investigación del Cáncer de Salamanca – IBMCC (CIC – USAL), Spain
Miguel Bastos Boente holds a Bachelor's degree in Biotechnology from the University of Salamanca and a Master's degree in Biology and Cancer Clinic from the same institution. Since July 2020, he has been part of the Molecular Biology and HLA Laboratory at the University Hospital of Salamanca, where he focuses on the study of chronic lymphoproliferative syndromes (CLL and lymphomas).
Currently, his doctoral research centers on unraveling resistance mechanisms to BTK and BCL2 inhibitors in chronic lymphocytic leukemia (CLL). He has hands-on experience in next-generation sequencing (NGS) technologies, as well as bioinformatic and biostatistical analysis. As part of his PhD, he has developed a custom NGS panel to assess mutational profiles in pharmacological resistance genes, including BTK, PLCG2, and BCL2.
In addition, he is working on the development of a neural network-based model for the diagnosis of chronic lymphoproliferative syndromes, integrating flow cytometry (FC), copy number variations, and translocation data.
